Skip to main content

Advertisement

Table 1 Baseline characteristics of 39 patients with high-risk non-Hodgkin’s lymphoma

From: Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

Characteristic R-CHOP [cases (%)] CHOP [cases (%)] P value
Total 14 25  
Sex    0.673
 Male 8 (57.1) 16 (64.0)  
 Female 6 (42.9) 9 (36.0)  
Tumor origin    <0.001
 B-cell 14 (100.0) 8 (32.0)  
 T-cell 0 15 (60.0)  
 NA 0 2 (8.0)  
Ann arbor stage    0.119
 I/II 1 (7.1) 8 (32.0)  
 III/IV 13 (92.9) 17 (68.0)  
ECOG score    0.289
 <2 13 (92.9) 23 (92.0)  
 ≥2 1 (7.1) 2 (8.0)  
LDH level (IU/L)    0.328
 >225 9 (64.3) 12 (48.0)  
 ≤225 5 (35.7) 13 (52.0)  
B symptoms    0.089
 No 5 (35.7) 16 (64.0)  
 Yes 9 (64.3) 9 (36.0)  
Bulky disease    0.431
 No 6 (42.9) 14 (56.0)  
 Yes 8 (57.1) 11 (44.0)  
Extranodal invasion    0.652
 No 3 (21.4) 7 (28.0)  
 Yes 11 (78.6) 18 (72.0)  
aaIPI    0.096
 0–1 4 (28.6) 15 (60.0)  
 2–3 10 (71.4) 10 (20.0)  
Disease status before mobilization   0.201
 CR 8 (57.1) 9 (36.0)  
 PR 6 (42.9) 16 (64.0)  
Previous radiation therapy 0 2 (8.0) 0.528
  1. R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimen; CHOP, CHOP or CHOP-like regimen without rituximab; ECOG Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; aaIPI age-adjusted International Prognostic Index; CR complete response; PR partial response; NA not available